CELLECTIS news, videos and press releases
For more news please use our advanced search feature.
CELLECTIS - More news...
CELLECTIS - More news...
- Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
- Monthly information on share capital and company voting rights
- Monthly information on share capital and company voting rights
- Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
- Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
- Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
- Cellectis Provides Financial Results for the Second Quarter 2024
- Monthly information on share capital and company voting rights
- FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
- FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
- Monthly information on share capital and company voting rights
- Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
- Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
- Monthly information on share capital and company voting rights
- Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
- Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
- Cellectis Reports Financial Results for First Quarter 2024
- Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
- Monthly information on share capital and company voting rights
- Monthly information on share capital and company voting rights
- Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
- Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
- Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
- Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
- Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
- Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
- Monthly information on share capital and company voting rights
- Monthly information on share capital and company voting rights
